Pure lab peptides MOTS-c 20 mg | Supports Mitochondrial Health and Metabolic Flexibility

In the evolving landscape of cellular biology, mitochondria have long been celebrated as the “powerhouses” of the cell. However, recent scientific breakthroughs have revealed their role as sophisticated metabolic regulators through the production of signaling molecules known as mitokines. MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) sits at the center of this paradigm shift, acting as a mitochondrial-derived peptide that communicates directly with the cell nucleus to maintain metabolic homeostasis and vitality.

The Science of Mitokine Signaling

Unlike the majority of mitochondrial proteins which are encoded by nuclear DNA, MOTS-c is unique because it is encoded by the mitochondrial genome itself. This 16-amino acid peptide serves as a systemic signaling molecule that orchestrates the “mitochondrial-to-nuclear” cross-talk. When a cell experiences metabolic stress—such as during intensive physical exertion or caloric restriction—MOTS-c translocates from the mitochondria to the nucleus. Once there, it functions as a regulator of gene expression, helping the cell adapt its energetic demands and restore internal balance.

The primary molecular mechanism of MOTS-c involves its interaction with the folate cycle. Specifically, the peptide inhibits the folate cycle at the level of 10-formyltetrahydrofolate dehydrogenase (ALDH1L1). This specific inhibition leads to an accumulation of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR). AICAR is recognized as a potent naturally occurring activator of AMP-activated protein kinase (AMPK). By elevating AICAR levels, MOTS-c effectively signals the cell to sense an energy deficit, thereby triggering a survival-level metabolic shift.

AMPK Activation and Metabolic Flexibility

The activation of the AMPK pathway by MOTS-c results in several critical metabolic responses. One of the most significant is the stimulation of GLUT4 transporters, which move to the cell membrane to allow for glucose uptake. This process supports healthy glucose metabolism and cellular insulin sensitivity independently of immediate insulin signaling. Furthermore, MOTS-c upregulates fatty acid oxidation, a process often referred to as “fat burning,” while inhibiting acetyl-CoA carboxylase (ACC) to reduce lipid synthesis. This dual action contributes to enhanced metabolic flexibility—the body’s ability to efficiently switch between fuel sources.

Beyond immediate energy regulation, research suggests that MOTS-c interacts with the PGC-1α pathway. This interaction is central to mitochondrial biogenesis, the process by which cells create new mitochondria. By maintaining a healthy population of efficient mitochondria, MOTS-c helps maintain cellular vitality and metabolic homeostasis, particularly during the natural aging process where mitochondrial function typically begins to decline.

Usage and Research Protocols

This product is provided as a 20 mg vial of lyophilized (freeze-dried) powder to maintain structural integrity and stability. Because MOTS-c is susceptible to digestive enzymes, it is not suitable for oral administration and is utilized in research via subcutaneous injection to ensure systemic absorption. In laboratory settings, researchers typically reconstitute the 20 mg vial with 2 ml of bacteriostatic water, yielding a concentration of 10 mg per milliliter.

Scientific literature often references research protocols with dosages ranging from 5 mg to 10 mg. Some studies utilize a “loading phase” involving more frequent applications (3-5 times per week) followed by a maintenance schedule of 1-2 times per week. It is essential to note that these are observations of existing scientific protocols and do not constitute clinical advice. The peptide should be stored in a cool, dark environment; once reconstituted, it must be refrigerated and used within a specific timeframe to ensure efficacy.

Safety and Compliance Information

MOTS-c is an endogenously produced molecule, yet exogenous application in a research context requires careful consideration. Due to its powerful activation of the AMPK pathway, it has the potential to significantly lower blood sugar. Close monitoring for symptoms of hypoglycemia is essential during research. Furthermore, as MOTS-c promotes metabolic efficiency and glucose uptake, some theoretical models suggest it could support the energy demands of hyper-metabolic cells; therefore, it is generally contraindicated for subjects with active malignancies or high oncological risk.

Important Notice: This peptide is strictly for Research Use Only (RUO) and is not FDA-approved for medical treatment or as a dietary supplement. Safety data for pregnant or breastfeeding individuals has not been established. This product is not intended to diagnose, treat, cure, or prevent any disease.

Frequently Asked Questions